Hang Cao, Xuejun Li*, Feiyifan Wang, Yueqi Zhang, Yi Xiong and Qi Yang Pages 599 - 629 ( 31 )
Glioma, especially its most malignant type, Glioblastoma (GBM), is the most common and the most aggressive malignant tumour in the central nervous system. Currently, we have no specific therapies that can significantly improve its dismal prognosis. Recent studies have reported promising in vitro experimental results of several novel glioma-targeting drugs; these studies are encouraging to both researchers and patients. However, clinical trials have revealed that novel compounds that focus on a single, clear glioma genetic alteration may not achieve a satisfactory outcome or have side effects that are unbearable. Based on this consensus, phytochemicals that exhibit multiple bioactivities have recently attracted much attention. Traditional Chinese medicine and traditional Indian medicine (Ayurveda) have shown that phytocompounds inhibit glioma angiogenesis, cancer stem cells and tumour proliferation; these results suggest a novel drug therapeutic strategy. However, single phytocompounds or their direct usage may not reverse comprehensive malignancy due to poor histological penetrability or relatively unsatisfactory in vivo efficiency. Recent research that has employed temozolomide combination treatment and Nanoparticles (NPs) with phytocompounds has revealed a powerful dual-target therapy and a high blood-brain barrier penetrability, which is accompanied by low side effects and strong specific targeting. This review is focused on major phytocompounds that have contributed to glioma-targeting treatment in recent years and their role in drug resistance inhibition, as well as novel drug delivery systems for clinical strategies. Lastly, we summarize a possible research strategy for the future.
Phytochemical, glioma, glioblastoma, drug resistance, drug delivery system, nanoparticles.
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha